Brief: Viracta Therapeutics Announces Orphan Drug Designation Granted By The European Commission To Nana-Val For The Treatment Of Diffuse Large B-Cell Lymphoma
19/01/2023 13:47
Jan 19 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
BY THE EUROPEAN COMMISSION TO NANA-VAL FOR THE TREATMENT OF
DIFFUSE LARGE B-CELL LYMPHOMA
Source text for Eikon: ID:nGNX1f46vT
Further company coverage: VIRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update